rawpixel-shutterstock-com-5

Rawpixel / Shutterstock.com

29 October 2015Americas

Pfizer and Allergan merger talks at early stage

Pharmaceutical company Pfizer has confirmed it has entered into talks with generics company Allergan over a potential merger.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

AstraZeneca ‘has value’ says former Pfizer lawyer

28 April 2014 AstraZeneca’s portfolio does not appear to offer a long pipeline of marketed products with long periods of exclusivity, says Jason Rutt, head of the patents group at Rouse in London and former head of Pfizer’s UK patent department.

Biotechnology

Pfizer to collaborate with Imcyse on new immunotherapy programme

5 February 2021 Pfizer has struck a research and licensing agreement with Belgium biopharmaceutical company Imcyse to develop treatments for rheumatoid arthritis using Imotopes - Imcyse’s platform of immunotherapeutics based on synthetic peptides.

More on this story

AstraZeneca ‘has value’ says former Pfizer lawyer

28 April 2014 AstraZeneca’s portfolio does not appear to offer a long pipeline of marketed products with long periods of exclusivity, says Jason Rutt, head of the patents group at Rouse in London and former head of Pfizer’s UK patent department.

Biotechnology

Pfizer to collaborate with Imcyse on new immunotherapy programme

5 February 2021 Pfizer has struck a research and licensing agreement with Belgium biopharmaceutical company Imcyse to develop treatments for rheumatoid arthritis using Imotopes - Imcyse’s platform of immunotherapeutics based on synthetic peptides.

More on this story

AstraZeneca ‘has value’ says former Pfizer lawyer

28 April 2014 AstraZeneca’s portfolio does not appear to offer a long pipeline of marketed products with long periods of exclusivity, says Jason Rutt, head of the patents group at Rouse in London and former head of Pfizer’s UK patent department.

Biotechnology

Pfizer to collaborate with Imcyse on new immunotherapy programme

5 February 2021 Pfizer has struck a research and licensing agreement with Belgium biopharmaceutical company Imcyse to develop treatments for rheumatoid arthritis using Imotopes - Imcyse’s platform of immunotherapeutics based on synthetic peptides.

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts

WBD to merge with firm to create ‘powerhouse’ practice

‘Be prepared, and don’t assume at the UPC’: Christopher Stothers